Streetbeat News

Stock Prices

USIO

Usio (NASDAQ:USIO) is scheduled to release its quarterly earnings report on March 27, 2024, with analysts expecting an EPS of $0.00. The company's past earnings performance shows a mix of misses and beats, with the stock price reacting accordingly. Shares are currently trading at $1.61, reflecting a 9.09% increase over the last 52 weeks. Investors are looking forward to not just the earnings results but also the company's guidance for future growth.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm

SOFI

Eight analysts have recently shared their views on SoFi Technologies (NASDAQ:SOFI), with opinions ranging from bullish to bearish. The 12-month price targets show an average of $8.38, down from $10.00, with a high of $12.00 and a low of $3.00. Analyst actions include both downgrades and maintenance of ratings, reflecting changing market dynamics and company performance. SoFi, a financial-services company, has shown notable revenue growth and a strong net margin but faces challenges in ROE and ROA. Its market capitalization is below the industry average, and it has a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm

SLE

Super League Enterprise (NASDAQ:SLE) is scheduled to release its quarterly earnings report on March 27, 2024, with an expected EPS of $-1.20. Analysts and investors are keen on whether the company will surpass this estimate and provide positive guidance for the next quarter. Historical data shows a mixed reaction to past earnings, with share prices fluctuating based on performance and guidance. Currently, SLE's shares are trading at $2.345, marking an 81.31% decline over the last year, indicating a bearish sentiment among long-term shareholders.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:01 pm

BEKE

KE Holdings Inc. (NYSE:BEKE) reported a net profit of 5.89 billion yuan for 2023, a significant turnaround from a 1.4 billion yuan loss in 2022. The company's revenue increased by 28.2% to 77.8 billion yuan. KE Holdings also announced a final dividend of $0.351 per ADS, following a special interim dividend earlier in the year. Despite the downturn in China's property market, KE Holdings expanded its market share and reduced the turnover days for accounts receivable in new home transactions. The company's non-brokerage services also saw significant growth, and it maintained a strong capital position, including a $719 million ADS buyback program.

Portfolio Pulse from The Bamboo Works

March 26, 2024 | 4:00 pm

GLYC

GlycoMimetics (NASDAQ:GLYC) is scheduled to release its quarterly earnings report on March 27, 2024, with an expected EPS of $-0.15. Historical data shows mixed reactions to past earnings results, with the last quarter's miss leading to no change in stock price. Over the last year, GLYC shares have increased by 120.47%, indicating a positive trend. Investors are keen on both the earnings outcome and the company's future guidance.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

SSKN

Strata Skin Sciences (NASDAQ:SSKN) is scheduled to release its quarterly earnings report on March 27, 2024, with an expected EPS of $-0.02. Historical data shows that the company's stock price reacts significantly to earnings beats or misses and guidance. Last quarter, SSKN beat the EPS estimate, resulting in a 15.62% share price increase the following day. However, over the last year, SSKN shares have declined by 55.58%, indicating potential investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

ABBV

The analysis of AbbVie (NYSE:ABBV) against its biotechnology industry competitors reveals a mixed financial health. AbbVie's PE ratio is significantly higher than the industry average, suggesting overvaluation. However, its PS ratio indicates potential undervaluation based on sales. The company's ROE is below the industry average, pointing to inefficiency in profit generation from equity. Despite this, AbbVie has a high EBITDA and gross profit, indicating strong profitability. Its revenue growth is lower than the industry average, raising concerns about future growth prospects. The debt-to-equity ratio places AbbVie in a moderate position among its peers.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

ITW

Over the past 10 years, Illinois Tool Works (NYSE:ITW) has outperformed the market with an annualized return of 12.47%, turning a $1000 investment into $3,274.56 today. The company currently has a market capitalization of $79.42 billion.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

AAPL

The article provides a detailed comparison of Apple (AAPL) against its competitors in the Technology Hardware, Storage & Peripherals industry, focusing on financial metrics like P/E, P/B, P/S ratios, ROE, EBITDA, gross profit, and revenue growth. Apple shows potential undervaluation based on its P/E ratio, high asset valuation as per its P/B ratio, strong revenue generation capability indicated by its P/S ratio, and efficient operations reflected in its high ROE, EBITDA, and gross profit. However, its lower revenue growth compared to the industry average suggests a need for strategies to enhance sales.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm

NVO

Over the past 10 years, Novo Nordisk (NYSE:NVO) has produced an average annual return of 19.04%, outperforming the market by 8.32% on an annualized basis. A $1000 investment in NVO a decade ago would be worth $5,657.39 today. Novo Nordisk currently has a market capitalization of $580.63 billion.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 4:00 pm